Health
FDA revokes EUA for monoclonal antibody therapy bamlanivimab to treat patients with COVID-19 – News-Medical.Net
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab,…
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment…
-
Business21 hours agoThe pros and cons of buying CBA shares in September
-
Noosa News21 hours agoRent changes on way for hundreds of social housing recipients following government review
-
Business17 hours agoWhere will Berkshire Hathaway be in 1 year?
-
Noosa News19 hours agoPolice reject claims about detained protester; SEQ train lines to be disrupted; BlueCare to cut enrolled nurses